ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more
ExpreS2ion Biotech Holding AB (EXPRS2) - Total Liabilities
Latest total liabilities as of December 2025: Skr29.42 Million SEK
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has total liabilities worth Skr29.42 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ExpreS2ion Biotech Holding AB - Total Liabilities Trend (2013–2025)
This chart illustrates how ExpreS2ion Biotech Holding AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ExpreS2ion Biotech Holding AB Competitors by Total Liabilities
The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DTE ENERGY - Dusseldorf Stock Exchang
DU:DGY
|
Germany | €38.21 Billion |
|
Coppermoly Limited
F:5C5
|
Germany | €137.37K |
|
COACH
MU:COY
|
Germany | €10.75 Billion |
|
Sino Hua-An International Bhd
KLSE:2739
|
Malaysia | RM52.45 Million |
|
CNS Pharmaceuticals Inc
NASDAQ:CNSP
|
USA | $1.96 Million |
|
Optiva Inc
PINK:RKNEF
|
USA | $133.87 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down ExpreS2ion Biotech Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ExpreS2ion Biotech Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ExpreS2ion Biotech Holding AB (2013–2025)
The table below shows the annual total liabilities of ExpreS2ion Biotech Holding AB from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr29.42 Million | -26.65% |
| 2024-12-31 | Skr40.11 Million | +200.95% |
| 2023-12-31 | Skr13.33 Million | -60.84% |
| 2022-12-31 | Skr34.04 Million | +193.16% |
| 2021-12-31 | Skr11.61 Million | -52.24% |
| 2020-12-31 | Skr24.31 Million | +22.86% |
| 2019-12-31 | Skr19.79 Million | +56.37% |
| 2018-12-31 | Skr12.65 Million | +20.53% |
| 2017-12-31 | Skr10.50 Million | -10.54% |
| 2016-12-31 | Skr11.73 Million | +16.19% |
| 2015-12-31 | Skr10.10 Million | +222.22% |
| 2014-12-31 | Skr3.13 Million | +44.07% |
| 2013-12-31 | Skr2.18 Million | -- |